Bruker Q3 EPS Beats, $175M Impairment Deepens Loss
Bruker's Q3 non-GAAP EPS of $0.56 beat consensus by 33.7%, sparking a 12.9% rally to the analyst target. Yet GAAP losses deepened to -$0.81 per share after a $174.5M goodwill impairment on Bruker Spat
Bruker Q3 EPS Beats as $175M Impairment Deepens GAAP Loss
NEW YORK, November 5 —
Bruker Corporation (BRKR) delivered non-GAAP EPS of $0.56 in Q3 2026, beating consensus by 33.7% and triggering a 12.9% single-day rally to analyst consensus target, yet GAAP losses deepened to -$0.81 per share, nearly double last year's figure, after a goodwill impairment on Bruker Spatial Biology.
- Q3 non-GAAP operating margin expanded 400 bps year-over-year to 16.3%; $140M annualized cost-out program cited as primary driver.
- GAAP diluted loss per share deepened to -$0.81 from -$0.41, after $174.5M goodwill impairment on Bruker Spatial Biology.
- After the November 5 rally, shares at $63.79 sit essentially at analyst consensus target of $63.83.
The Cost-Cut Is Doing the Work
Bruker, which makes scientific instruments across four segments including NMR spectroscopy, mass spectrometry, X-ray and electron microscopy tools, and semiconductor metrology equipment, has posted three consecutive non-GAAP EPS beats after a miss four quarters ago, with a $140 million annualized cost-out program as the primary margin lever. Q3's 16.3% non-GAAP operating margin, up 400 basis points year-over-year, shows the program working: non-GAAP gross margin reached 51.3%, up 120 basis points. Free cash flow improved by $151 million year-over-year and the company paid down $58 million in debt, pushing net leverage to 2.4x, below its stated target.
What the Write-Down Reveals
The GAAP picture tells a different story. While non-GAAP EPS rose 24.4% year-over-year, the GAAP diluted loss per share deepened from -$0.41 to -$0.81, driven by $174.5 million in non-cash goodwill impairment on the Bruker Spatial Biology unit, already characterized as underperforming and at risk of further charges if progress stalls. The spatial biology and automation assets could continue to weigh on group profitability, per filings. Q3 organic revenue grew just 0.7%, and through nine months of 2026, organic revenue was essentially flat, with the 3.1% reported growth driven by acquisitions. BSI segment instrument revenue fell mid-single-digits organically in Q3; only aftermarket services grew, at high-single-digits.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| BRKR | $8.9B | 24.3x | +62.3% |
| BIO | $9.9B | 38.0x | +24.0% |
| CRL | $15.0B | 24.6x | +90.9% |
| ICLR | $15.0B | 17.3x | +26.9% |
| WAT | $44.5B | 27.4x | +26.0% |
| MTD | $33.6B | 32.4x | +19.7% |
A Stock Already at Its Price Target
After a 12.9% single-day move, Bruker shares closed at $63.79 on November 5, essentially at the analyst consensus price target of $63.83. At 24.4x forward P/E on non-GAAP earnings, with trailing GAAP EPS of -$1.10 and 16.0% of float sold short, the market is split between the cost-out recovery story and unresolved impairment risk. Management reaffirmed full-year 2026 guidance and offered a more positive preliminary 2027 view; that visibility is real. The question is whether spatial biology proves a one-time charge or the first of several. Run the DCF calculator against the cost-out assumptions, then run the free Bruker Corporation deep-dive →.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What was Bruker's Q3 EPS beat?
Bruker reported non-GAAP EPS of $0.56 in Q3 2026, beating consensus by 33.7%. The beat was driven by a $140M annualized cost-out program that expanded non-GAAP operating margin 400 basis points year-over-year to 16.3%, with gross margin reaching 51.3%, up 120 basis points.
Why did GAAP losses deepen despite the non-GAAP beat?
GAAP diluted loss per share deepened to -$0.81 from -$0.41 year-over-year after a $174.5M goodwill impairment on Bruker Spatial Biology, characterized as underperforming. Management indicated the spatial biology and automation assets could continue to weigh on group profitability if progress stalls.
What's the real problem with Bruker's organic growth?
Q3 organic revenue grew just 0.7%, and through nine months of 2026 organic revenue was essentially flat. The Bruker Spatial Biology segment saw instrument revenue fall mid-single-digits organically in Q3, with only aftermarket services growing at high-single-digits.
Where does Bruker stock trade after the rally?
After a 12.9% single-day move on November 5, Bruker closed at $63.79, essentially at the analyst consensus price target of $63.83. At 24.4x forward P/E on non-GAAP earnings with 16% of float sold short, the market splits between the cost-out recovery story and unresolved impairment risk.
Bruker Corporation posted Q3 2026 non-GAAP EPS that beat consensus by 33.7% and sent shares up 12.9% to $63.79 on November 5, 2026, yet GAAP losses deepened to -$0.81 per share — nearly double the prior-year figure — after a $174.5 million goodwill impairment on Bruker Spatial Biology. The stock now sits essentially at analyst consensus target, leaving investors to judge whether the cost-cut margin story is durable enough to absorb further write-downs.